Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of tumor viability at second-look procedures performed before completing treatment on the Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV, 1991-1997: a report from the children's oncology group.
Raney B, Stoner J, Anderson J, Andrassy R, Arndt C, Brown K, Crist W, Maurer H, Qualman S, Wharam M, Wiener E, Meyer W, Hayes-Jordan A; Soft-Tissue Sarcoma Committee of the Children's Oncology Group. Raney B, et al. J Pediatr Surg. 2010 Nov;45(11):2160-8. doi: 10.1016/j.jpedsurg.2010.07.021. J Pediatr Surg. 2010. PMID: 21034938 Free PMC article. Clinical Trial.
Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from The Intergroup Rhabdomyosarcoma Study-IV, 1991-1997.
Raney RB, Stoner JA, Walterhouse DO, Andrassy RJ, Donaldson SS, Laurie F, Meyer WH, Qualman SJ, Crist WM; Intergroup Rhabdomyosarcoma Study-IV, 1991-1997. Raney RB, et al. Among authors: meyer wh. Pediatr Blood Cancer. 2004 Jun;42(7):618-25. doi: 10.1002/pbc.20012. Pediatr Blood Cancer. 2004. PMID: 15127417
Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: a report from the Children's Oncology Group.
Raney RB, Anderson JR, Brown KL, Huh WW, Maurer HM, Meyer WH, Parham DM, Rodeberg DA, Wolden SL, Donaldson SS; Soft-Tissue Sarcoma Committee of the Children's Oncology Group Arcadia California USA. Raney RB, et al. Among authors: meyer wh. Pediatr Blood Cancer. 2010 Oct;55(4):612-6. doi: 10.1002/pbc.22520. Pediatr Blood Cancer. 2010. PMID: 20806360 Free PMC article.
Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan AA, Parham DM, Cripe TP, Anderson JR, Meyer WH, Hawkins DS. Walterhouse DO, et al. Among authors: meyer wh. J Clin Oncol. 2014 Nov 1;32(31):3547-52. doi: 10.1200/JCO.2014.55.6787. Epub 2014 Sep 29. J Clin Oncol. 2014. PMID: 25267746 Free PMC article. Clinical Trial.
Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan A, Parham DM, Cripe TP, Anderson JR, Meyer WH, Hawkins DS. Walterhouse DO, et al. Among authors: meyer wh. Cancer. 2017 Jun 15;123(12):2368-2375. doi: 10.1002/cncr.30613. Epub 2017 Feb 17. Cancer. 2017. PMID: 28211936 Free PMC article.
Patterns of chemotherapy-induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Gupta AA, Chi YY, Anderson JR, Lyden E, Weigel B, Arndt C, Meyer WH, Rosenberg A, Hawkins DS. Gupta AA, et al. Among authors: meyer wh. Pediatr Blood Cancer. 2017 Sep;64(9):10.1002/pbc.26479. doi: 10.1002/pbc.26479. Epub 2017 Mar 23. Pediatr Blood Cancer. 2017. PMID: 28333415 Free PMC article.
Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Hawkins DS, Chi YY, Anderson JR, Tian J, Arndt CAS, Bomgaars L, Donaldson SS, Hayes-Jordan A, Mascarenhas L, McCarville MB, McCune JS, McCowage G, Million L, Morris CD, Parham DM, Rodeberg DA, Rudzinski ER, Shnorhavorian M, Spunt SL, Skapek SX, Teot LA, Wolden S, Yock TI, Meyer WH. Hawkins DS, et al. Among authors: meyer wh. J Clin Oncol. 2018 Sep 20;36(27):2770-2777. doi: 10.1200/JCO.2018.77.9694. Epub 2018 Aug 9. J Clin Oncol. 2018. PMID: 30091945 Free PMC article. Clinical Trial.
213 results